AC
ABBV icon

Ascend Capital’s AbbVie ABBV Stock Holding History

Ascend Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-100,000
Closed -$5.92M – 97
2015
Q4 		$5.92M Hold
100,000
– – 0.21% 99
2015
Q3 		$5.44M Sell
100,000
-4,400
-4% -$286K 0.21% 85
2015
Q2 		$7.02M Buy
+104,400
New +$6.82M 0.23% 107

Other funds holding ABBV

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ascend Capital's ABBV Position: Q2 2017 in Review

Ascend Capital sold out of AbbVie (ABBV) in Q2 2017, closing a stake of 228,527 shares — an estimated $14.9M sold.

Ascend Capital first reported a position in ABBV in Q2 2013 and held it in 7 quarters. The position peaked at $43.5M in Q1 2015. 1,763 funds tracked by Wall St. Rank hold ABBV as of Q2 2017.

  • Ascend Capital reported no remaining AbbVie position as of Q2 2017 after selling out during the quarter.
  • Ascend Capital sold 228,527 AbbVie shares in Q2 2017, an estimated $14.9M.
  • Ascend Capital first reported a position in AbbVie in Q2 2013 and held it in 7 quarters.
  • Ascend Capital's AbbVie position peaked at $43.5M in Q1 2015.
  • 1,763 funds tracked by Wall St. Rank held AbbVie as of Q2 2017.

Based on Ascend Capital's 13F filing for Q2 2017, filed 11 Aug 2017.